Rare Diseases 2021: maintaining the human element in decentralised trials
AGTC’s director of patient enrollment discusses the importance of the human touch in decentralised rare disease clinical trials.
By
Simplifying Clinical Trials
Latest in
Simplifying Clinical Trials
Metabolic disorders therapy area most suitable for use of digital health tech in clinical trials: poll
Verdict has conducted a poll to assess which therapy areas are most suitable for the use of digital health technologies…
Small world: how decentralisation is improving paediatric clinical trials
Paediatric trials remain among the most challenging aspects of clinical research. Clinical Trials Arena sat down with Betsy Reid and…
By
Groundbreaking UK “mega-trial” will test existing drugs as new treatments for MS
In a world-first “mega-trial”, UK experts will test a range of drugs already approved for other illnesses for the treatment…
By
Arch Biopartners secures approval to amend LSALT Peptide trial protocols
Canadian firm Arch Biopartners has secured approval to make certain protocol amendments to the Phase II trial of its lead…
Partner content
How to increase efficiency and agility in oncology trials
It’s no secret that pharmaceutical and clinical trial industries are reluctant to adapt to technological changes. This may, at least…
Partner content
Why going digital is the right step for the pharma industry
There are several factors at play that explain this reticence to accept change in the pharma industry. For one, regulatory…
Partner content
How a digital approach to risk management is transforming the pharma industry
When it comes to simplifying clinical trials, the most important change companies can make is to embrace the 21st century…